- Eli Lilly & Co.
- Pfizer Inc.
- Johnson & Johnson
- Bristol-Myers Squibb Co.
- Elan Corp. PLC
- Satori Pharmaceuticals Inc.
- Medivation Inc.
- Myriad Genetics Inc.
- H. Lundbeck AS
- Quintiles Transnational Holdings Inc.
- Amylin Pharmaceuticals Inc.
- Alkermes PLC
- Icos Corp.
- ImClone Systems Inc.
- GlaxoSmithKline PLC
- Novartis AG
- Pfizer gains rights to Medivation's Dimebon; deal terminated
- Pfizer acquires Wyeth in $67bn deal
- AHP, Elan develop Alzheimer's vaccine; concluded
- Lundbeck to sell Myriad's Flurizan in Europe;terminated
- TPG-Axon provides Eli Lilly with funds for Alzheimer's trials
- Lilly licenses Amylin's diabetes drug; deal ends with rights returned to Amylin
- Lilly agrees to buy Icos for $2.1bn
- Lilly comes out on top with $70/share ImClone bid
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Your question has been successfully sent to the email address below and we will get back as soon as possible. email@example.com.
All fields are required.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.